QIAGEN N.V. QGEN recently announced the expansion of its digital PCR (dPCR) offering for the biopharma sector's cell and gene therapy development in partnership with Niba Labs. The recent development ...
Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy ...
Venlo, the Netherlands, Sept. 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal ...
QIAGEN N.V. QGEN recently launched its QIAcuityDx Digital PCR System, whose instrument and accessories are Food and Drug Administration (“FDA”) 510(k) approved and In Vitro Diagnostic Regulation ...
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions ...
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback